# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $180 ...
Truist Securities analyst Joon Lee reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 price target.
Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price ta...
Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price tar...
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $220 price target.
Stifel analyst Annabel Samimy maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $225 ...